Marrone Bio Innovations, Inc Closes $9.2 Million Public Offering Of Common Stock With Full Exercise Of Over-Allotment Option Post author:Sam Post published:April 30, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like Spark Gets FDA Greenlight for Luxturna, The First Gene Therapy for Eye Disease Approved in the U.S. December 18, 2017 Ionis Announces Submission of Marketing Authorization Application for Inotersen to the EMA November 2, 2017 Eli Lilly Looks Over Its Shoulder After Novo Nordisk Wins FDA Panel Backing for Diabetes Drug October 18, 2017
Spark Gets FDA Greenlight for Luxturna, The First Gene Therapy for Eye Disease Approved in the U.S. December 18, 2017
Ionis Announces Submission of Marketing Authorization Application for Inotersen to the EMA November 2, 2017
Eli Lilly Looks Over Its Shoulder After Novo Nordisk Wins FDA Panel Backing for Diabetes Drug October 18, 2017